DFDA

Autologous Stem Cell Transplant (ASCT)

Treatment for Burkitt Lymphoma

Typical Dosage: High-dose conditioning chemotherapy followed by stem cell reinfusion

Effectiveness
50%
Safety Score
25%
Clinical Trials
5
Participants
2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
High-dose conditioning chemotherapy followed by stem cell reinfusion
Time to Effect
Weeks to months for engraftment and recovery
Treatment Duration
3-4 weeks inpatient for transplant, months for recovery
Evidence Quality
MODERATE
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75,000
Monitoring:$200,000
Side Effect Mgmt:$125,000
Total Annual:$400,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$100,000/QALY
QALYs Gained
4
Outcome-Based Costs
Cost per Remission
$1,000,000
Autologous Stem Cell Transplant (ASCT) Outcomes

for Burkitt Lymphoma

Efficacy Outcomes
Overall Effectiveness
+50%
Remission Rate
+40%
Common Side Effects
Profound Myelosuppression
+95%
Severe Febrile Neutropenia/Infection
+80%
Severe Mucositis/Stomatitis
+85%
Nausea/Vomiting
+90%
Fatigue
+90%
Organ Toxicity (Renal, Hepatic, Pulmonary)
+30%
Secondary Malignancies (long term)
+7%

Sources:

researchgate.net
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Autologous Stem Cell Transplant (ASCT) in Burkitt Lymphoma

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT04491370RECRUITINGPHASE1, PHASE2
View Study
20 participants
INTERVENTIONAL
Valhalla, United States
Started: Aug 1, 2021
Completed Clinical Trials
4 completed trials for Autologous Stem Cell Transplant (ASCT) in Burkitt Lymphoma

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

NCT00536601COMPLETEDNA
View Study
174 participants
INTERVENTIONAL
Buffalo, United States
Started: Jun 29, 2006

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00073918COMPLETEDPHASE2
View Study
111 participants
INTERVENTIONAL
Seattle, United States
Started: Feb 1, 1999

Radiation Therapy in Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation

NCT00031668COMPLETEDNA
View Study
6 participants
INTERVENTIONAL
Calgary, Canada +8 more
Started: Jan 31, 2001

Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma

NCT01516593COMPLETEDPHASE2
View Study
19 participants
INTERVENTIONAL
Aviano (PN), Italy +7 more
Started: Nov 1, 2011